Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Delaware Health News Online.
Press releases published on August 13, 2025
Vireo Growth Inc. Announces Second Quarter 2025 Results
GlobeNewswire
·
August 13, 2025
– Q2 GAAP revenue of $48.1 million increased 91% year-over-year, driven by recently-closed merger transactions – – Q2 pro forma financial results were in line with management’s previously communicated expectations – – Recent $153 million refinancing …
X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement
GlobeNewswire
·
August 13, 2025
BOSTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today closed an upsized private placement of 11,040,776 shares of common stock and pre- …
BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates
GlobeNewswire
·
August 13, 2025
Positive Phase 2 results for BX211 demonstrated >40% wound size reduction vs. placebo in diabetic foot osteomyelitis patients; Planning underway for potential registrational study Nature Communications publication of new BX004 Phase 1b/2a data demonstrated …
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease
GlobeNewswire
·
August 13, 2025
MALVERN, Pa., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Committee for Medicinal Products for Human Use (CHMP) …
Neuronascent Announces Progress for Lead Candidate NNI-362: Publication of Phase 1a Clinical Trial Results and FDA Grants Waiver of Fee for Canine Cognitive Disorder 2025 Submissions
GlobeNewswire
·
August 13, 2025
BALTIMORE., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Neuronascent Inc., a privately-held neuron regeneration therapeutics company, today announced that the Phase 1a trial in aged human subjects of its NNI-362 therapy was published in Alzheimer’s Research and …
Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
August 13, 2025
With the clearance of the U.S. IND, initiation of the U.S. clinical trial of AXN-2510/IMM2510 (“‘2510”) anticipated before the end of 2025 Updated ‘2510 monotherapy data in squamous-NSCLC to be presented at IASLC’s 2025 World Conference on Lung Cancer ( …
Scilex Holding Company (Nasdaq: SCLX) Announces Effectiveness of Registration Statement on Form S-4 for the Proposed Business Combination of Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, Inc., a Majority-Owned Subsidiary of Scilex
GlobeNewswire
·
August 13, 2025
Denali’s registration statement on Form S-4 declared effective by the Securities and Exchange Commission Extraordinary general meeting of Denali Capital Acquisition Corp. shareholders to approve the proposed business combination is scheduled to be held on …
Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania
GlobeNewswire
·
August 13, 2025
STAFFORD, Texas, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy …
LIO Launches Next-Generation Inpatient Mental Health Platform with Advanced Rounding, Monitoring, and Compliance Tools
GlobeNewswire
·
August 13, 2025
WILMINGTON, Del., Aug. 13, 2025 (GLOBE NEWSWIRE) -- LIO today announced the launch of its new all-in-one platform for inpatient mental health services, featuring a compliance reporting suite, next generation digital observations, and adaptive monitoring …
Corza Medical Launches Biomedical Textiles Innovation Lab to Accelerate OEM Product Development
GlobeNewswire
·
August 13, 2025
TAUNTON, U.K., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Corza Medical, a leading global manufacturer of surgical technologies and medical device components announced today the launch of its Biomedical Textiles Innovation Lab, a state-of-the-art facility designed …
Greywolf Therapeutics begins dosing of the first treatment to target the antigenic source of autoimmunity
GlobeNewswire
·
August 13, 2025
This is the first ever autoimmunity study to evaluate a potential functional cure that targets the antigenic source – the origin of autoimmune disease The Phase 1/2 study (up to 141 participants) will evaluate the safety, tolerability and efficacy of …
Santhera schließt Vereinbarung mit GEN über den Vertrieb von AGAMREE® (Vamorolon) in der Türkei
GlobeNewswire
·
August 13, 2025
Pratteln, Schweiz, 13. August 2025 – Santhera Pharmaceuticals (SIX: SANN) gibt die Unterzeichnung einer exklusiven Vereinbarung mit Gen İlaç ve Sağlık Ürünleri San. ve Tic. A.Ş. (GEN) über den Vertrieb und die Vermarktung von AGAMREE® (Vamorolon) in der …
Santhera Secures Agreement with GEN for the Distribution of AGAMREE® (Vamorolone) in Türkiye
GlobeNewswire
·
August 13, 2025
Pratteln, Switzerland, 13 August, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Gen İlaç ve Sağlık Ürünleri San. ve Tic. A.Ş. (GEN) for the distribution and promotion of AGAMREE® (vamorolone) in Türkiye …
Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering
GlobeNewswire
·
August 13, 2025
BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today …
Global High-Throughput Screening Market to Surpass USD 50.2 Billion by 2029 | MarketsandMarkets™.
GlobeNewswire
·
August 13, 2025
Delray Beach, FL, Aug. 12, 2025 (GLOBE NEWSWIRE) -- North America Leads Today, Asia Pacific to Record Fastest Growth The global high throughput screening market, valued at US$25.7 billion in 2023, stood at US$28.8 billion in 2024 and is projected to …